Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre
July 13, 2022
July 13, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functional and psilocybin mushroom strains for transformational human experiences, is pleased to announce that it has finalized a... Read more
Ryan Allway May 27th, 2022 Psychedelics, Top News Halucenex to receive recently harvested first batch of psilocybe cubensis May 27, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human... Read more
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program
February 16, 2022
VANCOUVER, BC (GLOBE NEWSWIRE – February 16, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Health Canada has added the... Read more
Rapid Dose Therapeutics Signs Product Supply Agreement with Oakland Health Limited in the United Kingdom
December 9, 2021
Ryan Allway December 9th, 2021 BURLINGTON, Ontario, December 09, 2021–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company“) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, entered into an agreement on Friday, November 26, 2021 with Oakland Health Limited (“Oakland Health” operating as “RD Therapeutics”) to supply... Read more
Clearmind Signs Development and Supply Agreement to Produce Its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences
October 26, 2021
Ryan Allway October 26th, 2021 Psychedelics Output will be used to advance clinical testing of MEAI as a treatment for Alcohol Use Disorder and Binge Drinking TORONTO, Ontario, Oct. 26, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the “Company“), a psychedelic medicine biotech... Read more
Willow Biosciences and Cellular Goods Announce Multiyear Supply Agreement for Cannabigerol (CBG)
June 10, 2021
Ryan Allway June 10th, 2021 VANCOUVER, BC, June 10, 2021 /CNW/ – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQX: CANSF), a biotechnology company producing ultra-pure, sustainably made compounds, and Cellular Goods PLC (“Cellular Goods“) (LSE: CBX), a U.K. based provider of premium consumer products based on biosynthetically made cannabinoids, are... Read more
